Esperion Therapeutics ( (ESPR) ) has released its Q2 earnings. Here is a breakdown of the information Esperion Therapeutics presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing oral, non-statin medications for cardiovascular disease prevention, particularly for patients with elevated LDL cholesterol levels. In its second quarter of 2025, Esperion reported a 12% year-over-year increase in total revenue, reaching $82.4 million, with U.S. net product revenue growing by 42% to $40.3 million. The company also achieved its first quarter of operating income from ongoing operations, marking a significant milestone in its financial performance. Key highlights include settlement agreements preventing generic versions of its drug NEXLETOL from entering the market before 2040 and strategic expansions in international markets, including Japan and Europe. Esperion’s research and development expenses decreased by 37% compared to the previous year, and the company reduced its net loss significantly from $61.9 million in Q2 2024 to $4.8 million in Q2 2025. Looking ahead, Esperion anticipates achieving sustainable profitability by the first quarter of 2026, driven by continued revenue growth and strategic market expansions.